Trials / Conditions / Norovirus Infections

Norovirus Infections

14 registered clinical trials studyying Norovirus Infections — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective NCT07358910	Institut Pasteur du Cambodge	—
Active Not Recruiting	A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ NCT06944717	Vaxart	Phase 1
Completed	A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their NCT07254728	Vaxart	Phase 1
Completed	Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Po NCT05916326	National Vaccine and Serum Institute, China	Phase 3
Completed	A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers NCT05626803	Vaxart	Phase 2
Completed	A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Ad NCT05213728	Vaxart	Phase 1
Completed	Norovirus Challenge Study NCT05212168	Vaxart	Phase 1 / Phase 2
Unknown	Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha) NCT04941261	National Vaccine and Serum Institute, China	Phase 2
Completed	Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines NCT04875676	Vaxart	Phase 1 / Phase 2
Completed	Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine NCT04854746	Vaxart	Phase 1
Completed	A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine NCT04188691	National Vaccine and Serum Institute, China	Phase 1
Completed	Admission Pattern Among Children With Gastro-intestinal Infections Before and During the Covid-19 Pandemic NCT06211621	Region Zealand	—
Terminated	Human Breastmilk in Young Children With Norovirus Infection of the Gut NCT02371538	Children's Hospital Medical Center, Cincinnati	N/A
Completed	Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1) NCT01435811	Children's Hospital Medical Center, Cincinnati	Phase 1